KR101290509B1 - 조혈성 신생물 및 백혈병의 치료를 위한 벤조디아제핀 유도체 - Google Patents

조혈성 신생물 및 백혈병의 치료를 위한 벤조디아제핀 유도체 Download PDF

Info

Publication number
KR101290509B1
KR101290509B1 KR1020117024044A KR20117024044A KR101290509B1 KR 101290509 B1 KR101290509 B1 KR 101290509B1 KR 1020117024044 A KR1020117024044 A KR 1020117024044A KR 20117024044 A KR20117024044 A KR 20117024044A KR 101290509 B1 KR101290509 B1 KR 101290509B1
Authority
KR
South Korea
Prior art keywords
leukemia
mll
delete delete
mixed
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117024044A
Other languages
English (en)
Korean (ko)
Other versions
KR20120004447A (ko
Inventor
마르씨오 체디드
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42174602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101290509(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20120004447A publication Critical patent/KR20120004447A/ko
Application granted granted Critical
Publication of KR101290509B1 publication Critical patent/KR101290509B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020117024044A 2009-04-14 2010-04-08 조혈성 신생물 및 백혈병의 치료를 위한 벤조디아제핀 유도체 Expired - Fee Related KR101290509B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16909409P 2009-04-14 2009-04-14
US61/169,094 2009-04-14
PCT/US2010/030315 WO2010120614A1 (en) 2009-04-14 2010-04-08 Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia

Publications (2)

Publication Number Publication Date
KR20120004447A KR20120004447A (ko) 2012-01-12
KR101290509B1 true KR101290509B1 (ko) 2013-07-26

Family

ID=42174602

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117024044A Expired - Fee Related KR101290509B1 (ko) 2009-04-14 2010-04-08 조혈성 신생물 및 백혈병의 치료를 위한 벤조디아제핀 유도체

Country Status (23)

Country Link
US (2) US8802668B2 (enExample)
EP (1) EP2419106A1 (enExample)
JP (1) JP5699129B2 (enExample)
KR (1) KR101290509B1 (enExample)
CN (1) CN102395372B (enExample)
AU (1) AU2010236747B2 (enExample)
BR (1) BRPI1013774A2 (enExample)
CA (1) CA2758473C (enExample)
CL (1) CL2011002531A1 (enExample)
DO (1) DOP2011000312A (enExample)
EA (1) EA018933B1 (enExample)
EC (1) ECSP11011403A (enExample)
IL (1) IL215107A0 (enExample)
MA (1) MA33184B1 (enExample)
MX (1) MX2011010937A (enExample)
MY (1) MY157218A (enExample)
NZ (1) NZ595413A (enExample)
PE (1) PE20120772A1 (enExample)
SG (1) SG175207A1 (enExample)
TN (1) TN2011000500A1 (enExample)
TW (1) TWI453022B (enExample)
UA (1) UA103792C2 (enExample)
WO (1) WO2010120614A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757356B2 (en) 2015-10-12 2017-09-12 Chonnam National University Hospital Composition comprising bio compound for treating cardiovascular disease

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120772A1 (es) 2009-04-14 2012-06-27 Lilly Co Eli Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia
WO2012125787A1 (en) 2011-03-17 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFβ AND RUNX1 PROTEINS
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
CN102887896B (zh) * 2012-10-26 2015-11-18 南京工业大学 一种2-（咪唑并[1,2-a]吡啶-3-基）乙腈的制备方法
WO2014090398A1 (en) * 2012-12-10 2014-06-19 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
CN104945436B (zh) * 2015-07-09 2017-02-08 山东罗欣药业集团股份有限公司 一种米诺膦酸的制备方法
WO2018083481A1 (en) 2016-11-03 2018-05-11 Ucl Business Plc Cancer therapy
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006043A2 (en) 2007-07-02 2009-01-08 Eli Lilly And Company Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
KR100974770B1 (ko) * 2002-03-05 2010-08-06 일라이 릴리 앤드 캄파니 키나제 억제제로서의 퓨린 유도체
ATE535241T1 (de) 2007-12-05 2011-12-15 Univ Mainz Johannes Gutenberg Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie
PE20120772A1 (es) 2009-04-14 2012-06-27 Lilly Co Eli Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006043A2 (en) 2007-07-02 2009-01-08 Eli Lilly And Company Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a]pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, 2004, Vol. 47, No. 16, pp. 3934-3937 *
Nature, 2008, Vol. 455, No. 7217, p. 1205 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757356B2 (en) 2015-10-12 2017-09-12 Chonnam National University Hospital Composition comprising bio compound for treating cardiovascular disease

Also Published As

Publication number Publication date
CA2758473C (en) 2013-12-17
JP2012524089A (ja) 2012-10-11
US8802668B2 (en) 2014-08-12
CN102395372B (zh) 2014-07-02
MY157218A (en) 2016-05-13
ECSP11011403A (es) 2011-11-30
TW201105328A (en) 2011-02-16
CA2758473A1 (en) 2010-10-21
CL2011002531A1 (es) 2012-06-01
KR20120004447A (ko) 2012-01-12
EP2419106A1 (en) 2012-02-22
IL215107A0 (en) 2011-12-29
JP5699129B2 (ja) 2015-04-08
SG175207A1 (en) 2011-11-28
EA201171243A1 (ru) 2012-03-30
AU2010236747B2 (en) 2012-11-08
BRPI1013774A2 (pt) 2016-04-05
PE20120772A1 (es) 2012-06-27
MX2011010937A (es) 2011-11-02
AU2010236747A1 (en) 2011-10-06
MA33184B1 (fr) 2012-04-02
UA103792C2 (uk) 2013-11-25
WO2010120614A1 (en) 2010-10-21
CN102395372A (zh) 2012-03-28
TN2011000500A1 (en) 2013-05-24
TWI453022B (zh) 2014-09-21
US20100261712A1 (en) 2010-10-14
US9044487B2 (en) 2015-06-02
DOP2011000312A (es) 2011-10-31
EA018933B1 (ru) 2013-11-29
NZ595413A (en) 2013-05-31
US20140235621A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
KR101290509B1 (ko) 조혈성 신생물 및 백혈병의 치료를 위한 벤조디아제핀 유도체
ES2928111T3 (es) Inhibición de la señalización AXL en terapia antimetastásica
Cicenas The Aurora kinase inhibitors in cancer research and therapy
CN106279142A (zh) 5‑[[4‑[[吗啉‑2‑基]甲基氨基]‑5‑(三氟甲基)‑2‑吡啶基]氨基]吡嗪‑2‑腈及其治疗应用
Sales et al. Stem cells and cancer: an overview
CN102083314A (zh) Parp抑制剂化合物、组合物以及使用方法
CN113811333A (zh) 靶向抗癌核激素受体的化合物
JP2020508326A (ja) ブルトン型チロシンキナーゼの阻害剤
CN111386264A (zh) 用于治疗t-细胞急性淋巴细胞白血病的化合物、组合物和方法
CN109789158A (zh) Runx抑制剂
US10548861B2 (en) Use of ureidomustine (BO-1055) in cancer treatment
CN101623277B (zh) 芬维a胺及其活性衍生物的新用途及其药物组合物
TW202535354A (zh) 可用於治療增殖性疾病或病症之化合物及組合物
JP2019514969A (ja) 分子イメージング及びがんの免疫療法のためのδオピオイド受容体標的化薬
US9173892B2 (en) Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same
Vine An investigation into the cytotoxic properties of isatin-derived compounds: potential for use in targeted cancer therapy
Molinaro Mechanism of action of a new organometallic compound inhibitor of topoisomerase I in adenocarcinomas
CN106573923A (zh) 苯氨基嘧啶衍生化合物，用于生产其的方法，所述化合物用于治疗癌症的用途和治疗方法
dos Santos Targeted Therapies in Breast Cancer
Santos Targeted therapies in breast cancer

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170723

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170723